Galderma to Present Extensive New Clinical Data Across Its Portfolio of Neuromodulators, Fillers and Biostimulators at the IMCAS World Congress 2022
Strong clinical data supporting Alluzience (abobotulinumtoxinA, ABO), the first liquid, ready-to-use neuromodulator as an effective and well-tolerated treatment for glabellar (frown) lines, with
Source: finanznachrichten.de